eCite Digital Repository

Safety and tolerability of oral lisdexamfetamine in adults with methamphetamine dependence: A phase-2 dose-escalation study

Citation

Ezard, N and Clifford, B and Dunlop, A and Bruno, R and Carr, A and Liu, Z and Siefried, KJ and Lintzeris, N, Safety and tolerability of oral lisdexamfetamine in adults with methamphetamine dependence: A phase-2 dose-escalation study, BMJ Open, 11, (5) pp. 1-13. ISSN 2044-6055 (2021) [Refereed Article]


Preview
PDF
801Kb
  

Copyright Statement

Copyright 2021 The Authors. Licensed under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) https://creativecommons.org/licenses/by-nc/4.0/

DOI: doi:10.1136/bmjopen-2020-044696

Abstract

Objectives: To examine the safety of an agonist-type treatment, lisdexamfetamine (LDX), at 250 mg/day among adults with methamphetamine (MA) dependence.

Design: A dose-escalating, phase-2, open-label, single-group study of oral LDX at two Australian drug treatment services.

Setting: The study was conducted at two Australian stimulant use disorder treatment clinics.

Participants: There were 16 participants: at least 18 years old, MA dependent for at least the preceding 2 years using ICD-10 criteria, reporting use of MA on at least 14 of the preceding 28 days.

Interventions: Daily, supervised LDX of 100-250 mg, single-blinded to dose, ascending-descending regimen over 8 weeks (100-250 mg over 4 weeks; followed by 4-week dose reduction regimen, 250-100 mg). Participants were followed through to week 12.

Outcomes: Primary outcomes were safety, drug tolerability and regimen completion at the end of week 4. Participants were followed to week 12. Secondary outcomes included: change in MA use; craving; withdrawal; severity of dependence; risk behaviour; change in other substance use; medication acceptability; potential for non-prescription use; adherence and neurocognitive functioning.

Results: Fourteen of 16 participants (87.5%) completed escalation to 250 mg/day. Two participants withdrew from the trial in the first week: one relocated away from the study site, the other self-withdrew due to a possible, known side effect of LDX (agitation). There was one serious adverse event of suicidal ideation which resolved. All other adverse events were mild or moderate in severity and known side effects of LDX. No participant was withdrawn due to adverse events. MA use decreased from a median of 21 days (IQR: 16-23) to 13 days (IQR: 11-17) over the 4-week escalation period (p=0.013).

Conclusions: LDX at a dose of up to 250 mg/day was safe and well tolerated by study participants, warranting larger trials as a pharmacotherapy for MA dependence.

Item Details

Item Type:Refereed Article
Keywords:clinical pharmacology, clinical trials, substance misuse
Research Division:Biomedical and Clinical Sciences
Research Group:Pharmacology and pharmaceutical sciences
Research Field:Clinical pharmacology and therapeutics
Objective Division:Manufacturing
Objective Group:Human pharmaceutical products
Objective Field:Human pharmaceutical treatments
UTAS Author:Bruno, R (Associate Professor Raimondo Bruno)
ID Code:146392
Year Published:2021
Web of Science® Times Cited:1
Deposited By:Psychology
Deposited On:2021-09-03
Last Modified:2021-10-28
Downloads:4 View Download Statistics

Repository Staff Only: item control page